• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

鉴定弥漫型胃癌的两基因标志物并建立预测总生存期的预后列线图。

Identification of a Two-Gene Signature and Establishment of a Prognostic Nomogram Predicting Overall Survival in Diffuse-Type Gastric Cancer.

机构信息

Digestive Medicine Center, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen 518107, China.

Department of Thoracic Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.

出版信息

Curr Oncol. 2022 Dec 23;30(1):171-183. doi: 10.3390/curroncol30010014.

DOI:10.3390/curroncol30010014
PMID:36661663
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9857582/
Abstract

BACKGROUND

It is widely acknowledged that the molecular biological characteristics of diffuse-type gastric cancer are different from intestinal-type gastric cancer. Notwithstanding that significant progress in high-throughput sequencing technology has been made, there is a paucity of effective prognostic biomarkers for diffuse gastric cancer for clinical practice.

METHODS

We downloaded four GEO datasets (GSE22377, GSE38749, GSE47007 and GSE62254) to establish and validate a prognostic two-gene signature for diffuse gastric cancer. The TGCA-STAD dataset was used for external validation. The optimal gene signature was established by using Cox regression analysis. Receiver operating characteristic (ROC) methodology was used to find the best prognostic model. Gene set enrichment analysis was used to analyze the possible signaling pathways of the two genes (MEF2C and TRIM15).

RESULTS

A total of four differently expressed genes (DEGs) (two upregulated and two downregulated) were identified. After a comprehensive analysis, two DEGs (MEF2C and TRIM15) were utilized to construct a prognostic model. A prognostic prediction model was constructed according to T stage, N stage, M stage and the expression of MEF2C and TRIM15. The area under the time-dependent receiver operator characteristic was used to evaluate the performance of the prognosis model in the GSE62254 dataset.

CONCLUSIONS

We demonstrated that MEF2C and TRIM15 might be key genes. We also established a prognostic nomogram based on the two-gene signature that yielded a good performance for predicting overall survival in diffuse-type gastric cancer.

摘要

背景

弥漫型胃癌的分子生物学特征不同于肠型胃癌，这一点已得到广泛认可。尽管高通量测序技术取得了重大进展，但对于弥漫型胃癌，临床上仍缺乏有效的预后生物标志物。

方法

我们下载了四个 GEO 数据集（GSE22377、GSE38749、GSE47007 和 GSE62254），用于建立和验证弥漫型胃癌的预后双基因signature。使用 TCGA-STAD 数据集进行外部验证。使用 Cox 回归分析建立最优基因 signature。使用接收器操作特征（ROC）方法寻找最佳预后模型。基因集富集分析用于分析这两个基因（MEF2C 和 TRIM15）的可能信号通路。

结果

共鉴定出四个差异表达基因（DEGs）（两个上调和两个下调）。经过综合分析，选取两个 DEGs（MEF2C 和 TRIM15）构建预后模型。根据 T 分期、N 分期、M 分期以及 MEF2C 和 TRIM15 的表达情况，构建了预后预测模型。使用时间依赖性接收器操作特征下的面积来评估预后模型在 GSE62254 数据集的性能。

结论

我们证明 MEF2C 和 TRIM15 可能是关键基因。我们还建立了一个基于双基因 signature 的预后列线图，该列线图在预测弥漫型胃癌的总生存期方面表现良好。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/62f8/9857582/d5321b52a061/curroncol-30-00014-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/62f8/9857582/73e92ce32229/curroncol-30-00014-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/62f8/9857582/7bb1d3af6985/curroncol-30-00014-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/62f8/9857582/c43a86c56112/curroncol-30-00014-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/62f8/9857582/32527db04c84/curroncol-30-00014-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/62f8/9857582/20e47a2a9b37/curroncol-30-00014-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/62f8/9857582/0b4a4f81cef2/curroncol-30-00014-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/62f8/9857582/d5321b52a061/curroncol-30-00014-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/62f8/9857582/73e92ce32229/curroncol-30-00014-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/62f8/9857582/7bb1d3af6985/curroncol-30-00014-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/62f8/9857582/c43a86c56112/curroncol-30-00014-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/62f8/9857582/32527db04c84/curroncol-30-00014-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/62f8/9857582/20e47a2a9b37/curroncol-30-00014-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/62f8/9857582/0b4a4f81cef2/curroncol-30-00014-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/62f8/9857582/d5321b52a061/curroncol-30-00014-g007.jpg

相似文献

1
Identification of a Two-Gene Signature and Establishment of a Prognostic Nomogram Predicting Overall Survival in Diffuse-Type Gastric Cancer.鉴定弥漫型胃癌的两基因标志物并建立预测总生存期的预后列线图。
Curr Oncol. 2022 Dec 23;30(1):171-183. doi: 10.3390/curroncol30010014.
2
Construction of mRNA prognosis signature associated with differentially expressed genes in early stage of stomach adenocarcinomas based on TCGA and GEO datasets.基于 TCGA 和 GEO 数据集构建与胃腺癌早期差异表达基因相关的 mRNA 预后特征。
Eur J Med Res. 2022 Oct 17;27(1):205. doi: 10.1186/s40001-022-00827-4.
3
A nomogram model based on the number of examined lymph nodes-related signature to predict prognosis and guide clinical therapy in gastric cancer.基于检查淋巴结数量相关特征的列线图模型预测胃癌的预后并指导临床治疗。
Front Immunol. 2022 Nov 2;13:947802. doi: 10.3389/fimmu.2022.947802. eCollection 2022.
4
Identification of a 6-lncRNA prognostic signature based on microarray re-annotation in gastric cancer.基于微阵列重新注释的胃癌 6-长链非编码 RNA 预后签名的鉴定。
Cancer Med. 2020 Jan;9(1):335-349. doi: 10.1002/cam4.2621. Epub 2019 Nov 19.
5
Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.基于统计分析构建新型膀胱癌 mRNA 特征预测预后模型。
BMC Cancer. 2021 Jul 27;21(1):858. doi: 10.1186/s12885-021-08611-z.
6
Construction and Validation of a Novel Prognostic Signature for Intestinal Type of Gastric Cancer.构建和验证一种新型的用于肠型胃癌的预后标志物。
Dis Markers. 2021 Aug 12;2021:5567392. doi: 10.1155/2021/5567392. eCollection 2021.
7
Angiogenesis-related lncRNAs predict the prognosis signature of stomach adenocarcinoma.血管生成相关长链非编码 RNA 预测胃腺癌的预后特征。
BMC Cancer. 2021 Dec 7;21(1):1312. doi: 10.1186/s12885-021-08987-y.
8
Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.鉴定胃癌中与铜死亡相关的亚型，构建预后模型和肿瘤微环境景观。
Front Immunol. 2022 Nov 21;13:1056932. doi: 10.3389/fimmu.2022.1056932. eCollection 2022.
9
A 9‑gene expression signature to predict stage development in resectable stomach adenocarcinoma.用于预测可切除胃腺癌分期发展的 9 基因表达特征。
BMC Gastroenterol. 2022 Oct 14;22(1):435. doi: 10.1186/s12876-022-02510-8.
10
Identification of an EMT-Related Gene Signature for Predicting Overall Survival in Gastric Cancer.用于预测胃癌总生存期的EMT相关基因特征的鉴定
Front Genet. 2021 Jun 24;12:661306. doi: 10.3389/fgene.2021.661306. eCollection 2021.

引用本文的文献

1
Construction of a prognostic model for gastric cancer based on immune infiltration and microenvironment, and exploration of MEF2C gene function.基于免疫浸润和微环境构建胃癌预后模型及MEF2C基因功能探索
BMC Med Genomics. 2025 Jan 14;18(1):13. doi: 10.1186/s12920-024-02082-4.
2
Identification of an autophagy- and macropinocytosis-related prognostic signature for the prediction of prognosis and therapeutic response in gastric cancer.鉴定与自噬和巨胞饮相关的预后标志物，用于预测胃癌的预后和治疗反应。
Genes Genomics. 2024 Oct;46(10):1149-1164. doi: 10.1007/s13258-024-01557-z. Epub 2024 Aug 16.

本文引用的文献

1
Molecular Characteristics, Clinical Significance, and Cancer Immune Interactions of Angiogenesis-Associated Genes in Gastric Cancer.胃癌中与血管生成相关基因的分子特征、临床意义和癌症免疫相互作用。
Front Immunol. 2022 Feb 22;13:843077. doi: 10.3389/fimmu.2022.843077. eCollection 2022.
2
Vascular Endothelial Growth Factor Receptors [VEGFR] as Target in Breast Cancer Treatment: Current Status in Preclinical and Clinical Studies and Future Directions.血管内皮生长因子受体 [VEGFR] 作为乳腺癌治疗的靶点：临床前和临床研究的现状及未来方向。
Curr Top Med Chem. 2022;22(11):891-920. doi: 10.2174/1568026622666220308161710.
3
Web-Based Survival Analysis Tool Tailored for Medical Research (KMplot): Development and Implementation.
专为医学研究量身定制的基于网络的生存分析工具（KMplot）：开发与应用
J Med Internet Res. 2021 Jul 26;23(7):e27633. doi: 10.2196/27633.
4
Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes.分析 2658 个人类癌症基因组中的遗传肿瘤内异质性。
Cell. 2021 Apr 15;184(8):2239-2254.e39. doi: 10.1016/j.cell.2021.03.009. Epub 2021 Apr 7.
5
RNA sequencing: new technologies and applications in cancer research.RNA 测序：癌症研究中的新技术和应用。
J Hematol Oncol. 2020 Dec 4;13(1):166. doi: 10.1186/s13045-020-01005-x.
6
Gastric cancer.胃癌。
Lancet. 2020 Aug 29;396(10251):635-648. doi: 10.1016/S0140-6736(20)31288-5.
7
Construction and validation of a TP53-associated immune prognostic model for gastric cancer.构建和验证与 TP53 相关的胃癌免疫预后模型。
Genomics. 2020 Nov;112(6):4788-4795. doi: 10.1016/j.ygeno.2020.08.026. Epub 2020 Aug 25.
8
Development and Validation of a Prognostic Nomogram for Gastric Cancer Based on DNA Methylation-Driven Differentially Expressed Genes.基于 DNA 甲基化驱动的差异表达基因构建胃癌预后列线图模型的建立与验证。
Int J Biol Sci. 2020 Feb 10;16(7):1153-1165. doi: 10.7150/ijbs.41587. eCollection 2020.
9
MEF2c-Dependent Downregulation of Myocilin Mediates Cancer-Induced Muscle Wasting and Associates with Cachexia in Patients with Cancer.MEF2c 依赖性下调肌球蛋白调节轻链介导癌症诱导的肌肉减少症，并与癌症患者恶病质相关。
Cancer Res. 2020 May 1;80(9):1861-1874. doi: 10.1158/0008-5472.CAN-19-1558. Epub 2020 Mar 4.
10
High Expression of TRIM15 Is Associated with Tumor Invasion and Predicts Poor Prognosis in Patients with Gastric Cancer.TRIM15 的高表达与胃癌的肿瘤侵袭相关，并预测患者预后不良。
J Invest Surg. 2021 Aug;34(8):853-861. doi: 10.1080/08941939.2019.1705443. Epub 2020 Jan 6.